salvia
Botanicalexperimental
Salvia is the largest genus of plants in the sage family Lamiaceae, with just under 1,000 species of shrubs, herbaceous perennials, and annuals. Within the Lamiaceae, Salvia is part of the tribe Mentheae within the subfamily Nepetoideae. One of several genera commonly referred to as sage, it includes two widely used herbs, Salvia officinalis and Salvia rosmarinus. — Wikipedia
Clinical trial activity
22 trials · 44 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
4
Phase 4
1
Earliest trial started Jul 1, 2005 (NCT00110552)
Timeline
Indications
Approved for
Studied for
- Altitude Sickness · Phase 3
- Alzheimer Disease · Phase 1
- Angina Pectoris · Phase 3
- COVID-19 · Phase 2/Phase 3
- Diabetes Mellitus · Phase 1/Phase 2
- Dyslipidemias · Phase 1/Phase 2
- Hyperuricemia · Phase 4
- Metabolic Syndrome · Phase 1/Phase 2
- Obesity · Phase 1/Phase 2
- Pharyngitis · Phase 3
- Respiratory Tract Infections · Phase 2/Phase 3
- Virus Diseases · Phase 2/Phase 3
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSalvia ↗
- WikipediaSalvia officinalis ↗
- WikipediaSalvia hispanica ↗
Also known as
- sage
- sage
- sage
- sage
- sage leaf allergenic extract
- salvia
- salvia
- salvia hispanica
- salvia hispanica l.
- salvia miltiorrhiza extract
- salvia officinalis
- salvia sample
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06703788 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2024 | Chang Gung University, Government of Taiwan |
| NCT06860763 | N/A | Oct 15, 2024 | Mahidol University, Peking University |
| NCT05936346 | N/A | Jul 17, 2023 | IBSA Institut Biochimique SA |
| NCT05497765 | N/A | Aug 1, 2022 | Guangdong Medical University, Guangzhou Medical University |
| NCT05360004 | Phase 2 | May 31, 2022 | Hong Kong Baptist University |
| NCT05269511 | N/A | Mar 10, 2022 | Hong Kong Baptist University |
| NCT04993729 | Phase 3 | Jul 21, 2021 | Tasly Pharmaceuticals, Inc., University of California, San Francisco |
| NCT05076058 | N/A | Mar 1, 2021 | Sun Yat-Sen University |
| NCT04705753 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2020 | Olvos Science SA, University of Crete, Vifor Inc. |
| NCT03789552 | Phase 3 | Jul 28, 2019 | Tasly Pharmaceuticals, Inc. |
| NCT03577938 | N/A | Sep 1, 2018 | Capital Medical University, China Medical University, Fudan University, Fuzhou Infectious Hospital, Government of China, Guangxi Medical University, Hangzhou Xixi hospital, Henan Medical University, Hepatobiliary Disease Hospital of Jilin Province, Jilin, China, Huazhong University of Science and Technology, Hubei University of Chinese Medicine, Hunan University of Traditional Chinese Medicine, Jilin University, People's Liberation Army of China, Shanghai University of Traditional Chinese Medicine, Shenzhen Third People's Hospital, Shenzhen University, Sun Yat-Sen University, Xiamen University |
| NCT03552263 | Phase 2 | Jun 7, 2018 | Tasly Pharmaceuticals, Inc., University of California, San Francisco |
| NCT03218709 | Phase 4 | Jan 31, 2017 | Sun Yat-Sen University |
| NCT02480673 | N/A | Jun 1, 2015 | Instituto Mexicano del Seguro Social |
| NCT02099097 | N/A | Mar 24, 2014 | Memorial Sloan-Kettering Cancer Center, New York University |
| NCT02067572 | N/A | Mar 12, 2014 | Lovisenberg Diakonale Hospital, University of Oslo |
| NCT01613183 | N/A | May 31, 2012 | China Academy of Chinese Medical Sciences |
| NCT01563770 | N/A | Apr 1, 2012 | Radboud University |
| NCT00728065 | N/A | Dec 1, 2007 | University of Toronto |
| NCT00707902 | Phase 3 | Feb 1, 2006 | Bioforce AG |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (44)
44 organizations
Page 1 / 3